Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05509426
Other study ID # 21063
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date November 2023

Study information

Verified date September 2022
Source University of Nottingham
Contact Roshan das Nair, PhD
Phone +44(0)115 8230589
Email roshan.dasnair@nottigham.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over the last 20 years, there have been many studies investigating the efficacy of attention and memory rehabilitation for people with multiple sclerosis (MS) however, there appears to be a lack of conclusive evidence regarding the true effectiveness of this intervention. This could be because the participant samples recruited to these studies are often extremely varied in terms of socio-demographics and clinical characteristics, and it would be very unlikely that all people with MS would benefit from these interventions uniformly. Therefore, there is a need to explore which subgroups of people with MS benefit most from cognitive rehabilitation so that this information can be used to help clinicians and services make decisions as to whom this intervention is offered. Cognitive rehabilitation is not routinely provided on the NHS due to lack of resources. This research is important as it will allow these resources to be optimised and made available to those who need them, but also to allow clinicians to understand whether their patient is likely to benefit from cognitive rehabilitation before it is offered. The primary aim of this study is to assess the feasibility and acceptability of undertaking a randomised controlled trial (RCT) to investigate the effectiveness of an online group-based cognitive rehabilitation programme with specific groups of people with MS. The secondary aim is to understand the impact that this intervention may have on various aspects of cognition such as memory, attention, and information processing. This will be assessed through various questionnaires and objective neuropsychological tests. In addition, an algorithm has been developed following the secondary data analysis of a large RCT investigating group-based cognitive rehabilitation for people with MS. This algorithm may be able to determine who benefits most from cognitive rehabilitation, we will therefore use this as part of the data analysis to understand if the algorithm has the potential to be an accurate clinical prediction tool. After completion of the cognitive rehabilitation, a small number of participants in the intervention group will be invited to take part in feedback interviews to give their views on the feasibility and acceptability of the group-based online cognitive rehabilitation and provide any suggestions for improvements for future trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date November 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - 18 or over and under 70 years of age. - Have MS, diagnosed at least 3 months prior to recruitment. - Have cognitive deficits, defined as performance below the 25th percentile on the Brief Repeatable Battery of Neuropsychological Tests (BRBN). - Able to speak English sufficiently to complete the cognitive assessments and take part in group sessions. - Have access to laptop or PC that supports MS Teams. - Able to give informed consent. Exclusion Criteria: - Vision or hearing problems, such that they are unable to complete the cognitive assessments, judged assessor. - Have concurrent severe medical or psychiatric conditions which would prevent participants from engaging in treatment, if allocated. - Are involved in other psychological intervention trials.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Rehabilitation
This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.

Locations

Country Name City State
United Kingdom Nottingham University Hospitals NHS Trust Nottingham

Sponsors (3)

Lead Sponsor Collaborator
University of Nottingham MS Society, University of Lincoln

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability and feasibility of conducting an online group-based cognitive rehabilitation programme. Feedback interviews will be conducted to understand the acceptability and feasibility of the intervention. Between the 3-month follow-up point and the 6-month follow-up point, up to 3 months.
Primary Appropriateness of eligibility criteria, baseline and outcome measures, recording of sessions, and randomisation protocol. Rates of enrolment and drop out will be recorded. Fidelity of the intervention will be assessed by video recording. From the date of randomisation to date of final follow-up, up to 1 year.
Primary Estimating sample size needed for Phase III RCT. Sample size calculations will be conducted during the primary analysis. From the start of the data analysis to study completion date, up to 6 months.
Primary Completion rates of outcome measures. Based on how many participants complete all of the outcome measures. 6 months.
Secondary Multiple Sclerosis Impact Scale-29 Non-cognitive questionnaire; Reliable Change Index between groups. Scores range from 9 to 36. Higher scores indicate greater psychological impact of MS on everyday life. Baseline, 3-months post randomisation, 6-month post randomisation
Secondary Everyday Memory Questionnaire-participant. Cognitive questionnaire; Reliable Change Index between groups. Scores range from 0 to 112. Higher scores indicate more frequent memory problems. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Everyday Memory Questionnaire-relative. Cognitive questionnaire; Reliable Change Index between groups. Scores range from 0 to 112. Higher scores indicate more frequent memory problems. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary General Health Questionnaire-30. Non-cognitive questionnaire; Reliable Change Index between groups. Scores range from 0 to 90. Higher scores indicate increased psychological distress. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Fatigue Severity Scale. Non-cognitive questionnaire; Reliable Change Index between groups. Scores range from -3.4 to 3.4. Higher scores indicate a greater impact of fatigue. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary EuroQol-5 Dimensions, five-level version. Non-cognitive questionnaire; Reliable Change Index between groups. Scores from 0 to 100. Higher scores indicate better overall health. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Guy's Neurological Disability Scale. Non-cognitive questionnaire; Reliable Change Index between groups. Scores range from 0 to 55. Higher scores indicate increased disability. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Brief Repeatable Battery of Neuropsychological Tests. Cognitive test; Reliable Change Index between groups. Scores ranges vary depending on the individual test. Higher scores indicate better performance. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Doors and People test. Cognitive test; Reliable Change Index between groups. Scores range from 0 to 20. Higher scores indicate better performance. Baseline, 3-months post randomisation, 6-month post randomisation.
Secondary Trail Making Test. Cognitive test; Reliable Change Index between groups. Scores range from 0 to 20. Higher scores indicate better performance. Baseline, 3-months post randomisation, 6-month post randomisation.
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis